EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enzymatic Remodelling of Tumour Microenvironment Enhances Anti‐CEACAM5 CAR T‐Cell Efficacy Against Colorectal Cancer

Debasis Banik iD, Christopher J Ward, Soura Chakraborty, Ziwei Zhang, Daniel Heraghty, Prasanna Suresh, Bing Li, Shekhar Kedia, Jhuma Pramanik, Simon J Davis, James P Roy, Michael A Chapman und 2 weitere

Advanced Science · 2026-03 · 13 (13)

DOI: 10.1002/advs.202509762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 22.01.2026. Verfasst von Debasis Banik und 13 weiteren Autor:innen. Beteiligte Einrichtung: Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Tumor Microenvironment, Colorectal Neoplasms, Carcinoembryonic Antigen, GPI-Linked Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions, Cancer Research UK (CRUK), NSF-BIO/UKRI-BBSRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T‐cell therapy has shown unprecedented success in haematological cancers but faces challenges in solid tumours. Although carcinoembryonic antigen‐related cell adhesion molecule 5 (CEACAM5) is differentially expressed in many solid tumours, anti‐CEACAM5 CAR T‐cells are ineffective. Here, we have studied the interaction of CEACAM5 targeting primary CAR T‐cells with colorectal cancer (CRC) cells using fluorescence microscopy. We found that CRC cells’ glycocalyx is much thicker than that of the CAR T cell causing delayed activation. Oscillating calcium fluxes, indicative of non‐sustained CAR T cell activation, are observed when CAR T cells interacted with CRC cells, which increased with increasing cell‐seeding time. Significant reduction in cytotoxicity is observed on going from early to longer‐seeded CRC monolayers. Imaging revealed that this effect correlated with a progressive loss of accessible CEACAM5 antigen on the CRC cell surface, possibly due to their sequestration in the intercellular junction, rendering CAR T cell engagement less effective. Local proteolytic treatment with trypsin to disrupt the CRC cell monolayer, using a micropipette, increased CEACAM5 availability, decreased glycocalyx thickness, and restored sustained CAR T cell calcium fluxes. Similar enhanced interaction is observed after treatment of CRC cell monolayer with hyaluronidase, approved for use in humans. Enzymatic treatment significantly enhanced CAR T cell‐mediated cytotoxicity and increased the percentage of TNF‐α–secreting CAR T cells. We observed limited availability of CEACAM5 on human colorectal cancer tissues, whereas treatment with trypsin or hyaluronidase increased accessibility. Our results reveal why CAR T cells targeting CEACAM5 are ineffective and suggest possible routes to improved therapy for CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentColorectal NeoplasmsCarcinoembryonic AntigenGPI-Linked ProteinsT-LymphocytesHumansCell Line, TumorImmunotherapy, AdoptiveReceptors, Chimeric Antigen

Stichwörter der Autor:innen

CAR T cellCEACAM5CRCenzymeglycocalyx

Substanzen

CEACAM5 protein, humanCarcinoembryonic AntigenGPI-Linked ProteinsReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
  • Department of Pathology, University of Cambridge, Cambridge, UK.
  • Radcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
  • Medical Research Council Translational Immune Discovery Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK.
  • MRC Toxicology Unit, University of Cambridge, Cambridge, UK.
  • Department of Haematology, University of Cambridge, Cambridge, UK.

ORCID-Profile: Debasis Banik, David Klenerman

Förderung

  • HORIZON EUROPE Marie Sklodowska-Curie Actions
  • Cancer Research UK (CRUK)
  • NSF-BIO/UKRI-BBSRC
  • MRC Project

Zitieren

APA

Banik, D., Ward, C. J., Chakraborty, S., Zhang, Z., Heraghty, D., Suresh, P., Li, B., Kedia, S., Pramanik, J., Davis, S. J., Roy, J. P., Chapman, M. A., Mahata, B., & Klenerman, D. (2026). Enzymatic Remodelling of Tumour Microenvironment Enhances Anti‐CEACAM5 CAR T‐Cell Efficacy Against Colorectal Cancer. Advanced Science, 13(13). https://doi.org/10.1002/advs.202509762

Vancouver

Banik D, Ward CJ, Chakraborty S, Zhang Z, Heraghty D, Suresh P, et al. Enzymatic Remodelling of Tumour Microenvironment Enhances Anti‐CEACAM5 CAR T‐Cell Efficacy Against Colorectal Cancer. Advanced Science. 2026;13(13). doi:10.1002/advs.202509762

BibTeX
@article{Banik2026,
  author = {Banik, Debasis and Ward, Christopher J and Chakraborty, Soura and Zhang, Ziwei and Heraghty, Daniel and Suresh, Prasanna and Li, Bing and Kedia, Shekhar and Pramanik, Jhuma and Davis, Simon J and Roy, James P and Chapman, Michael A and Mahata, Bidesh and Klenerman, David},
  title = {Enzymatic Remodelling of Tumour Microenvironment Enhances Anti‐CEACAM5 CAR T‐Cell Efficacy Against Colorectal Cancer},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {13},
  doi = {10.1002/advs.202509762}
}
Kostenlos starten →